vs
Side-by-side financial comparison of Albemarle Corporation (ALB) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.4B, roughly 2.0× Albemarle Corporation). Bausch Health Companies Inc. runs the higher net margin — -3.7% vs -29.0%, a 25.3% gap on every dollar of revenue. On growth, Albemarle Corporation posted the faster year-over-year revenue change (15.9% vs 9.3%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $233.1M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 2.4%).
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers...
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
ALB vs BHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.8B |
| Net Profit | $-414.2M | $-103.0M |
| Gross Margin | 13.9% | — |
| Operating Margin | -15.2% | 17.0% |
| Net Margin | -29.0% | -3.7% |
| Revenue YoY | 15.9% | 9.3% |
| Net Profit YoY | -650.1% | -205.1% |
| EPS (diluted) | $-3.88 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $2.8B | ||
| Q3 25 | $1.3B | $2.7B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.1B | $2.3B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $1.4B | $2.5B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $-414.2M | $-103.0M | ||
| Q3 25 | $-160.7M | $179.0M | ||
| Q2 25 | $22.9M | $148.0M | ||
| Q1 25 | $41.3M | $-58.0M | ||
| Q4 24 | $75.3M | $98.0M | ||
| Q3 24 | $-1.1B | $-85.0M | ||
| Q2 24 | $-188.2M | $10.0M | ||
| Q1 24 | $2.4M | $-64.0M |
| Q4 25 | 13.9% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 14.8% | — | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | -7.7% | — | ||
| Q2 24 | -0.7% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | -15.2% | 17.0% | ||
| Q3 25 | -16.6% | 23.1% | ||
| Q2 25 | 3.6% | 17.5% | ||
| Q1 25 | 1.8% | 12.2% | ||
| Q4 24 | 0.4% | 21.8% | ||
| Q3 24 | -81.9% | 12.7% | ||
| Q2 24 | -34.4% | 16.2% | ||
| Q1 24 | -13.2% | 13.1% |
| Q4 25 | -29.0% | -3.7% | ||
| Q3 25 | -12.3% | 6.7% | ||
| Q2 25 | 1.7% | 5.8% | ||
| Q1 25 | 3.8% | -2.6% | ||
| Q4 24 | 6.1% | 3.8% | ||
| Q3 24 | -78.9% | -3.4% | ||
| Q2 24 | -13.2% | 0.4% | ||
| Q1 24 | 0.2% | -3.0% |
| Q4 25 | $-3.88 | $-0.30 | ||
| Q3 25 | $-1.72 | $0.48 | ||
| Q2 25 | $-0.16 | $0.40 | ||
| Q1 25 | $0.00 | $-0.16 | ||
| Q4 24 | $0.29 | $0.24 | ||
| Q3 24 | $-9.45 | $-0.23 | ||
| Q2 24 | $-1.96 | $0.03 | ||
| Q1 24 | $-0.08 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.3B |
| Total DebtLower is stronger | $3.2B | $20.8B |
| Stockholders' EquityBook value | $9.5B | $-554.0M |
| Total Assets | $16.4B | $26.4B |
| Debt / EquityLower = less leverage | 0.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.8B | $1.7B | ||
| Q1 25 | $1.5B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.7B | $719.0M | ||
| Q2 24 | $1.8B | $595.0M | ||
| Q1 24 | $2.1B | $733.0M |
| Q4 25 | $3.2B | $20.8B | ||
| Q3 25 | $3.6B | $21.0B | ||
| Q2 25 | $3.6B | $21.7B | ||
| Q1 25 | $3.5B | $21.5B | ||
| Q4 24 | $3.5B | $21.6B | ||
| Q3 24 | $3.6B | $21.5B | ||
| Q2 24 | $3.5B | $21.7B | ||
| Q1 24 | $3.5B | $22.1B |
| Q4 25 | $9.5B | $-554.0M | ||
| Q3 25 | $10.0B | $-565.0M | ||
| Q2 25 | $10.2B | $-764.0M | ||
| Q1 25 | $10.0B | $-1.2B | ||
| Q4 24 | $10.0B | $-1.3B | ||
| Q3 24 | $10.2B | $-1.2B | ||
| Q2 24 | $11.2B | $-1.2B | ||
| Q1 24 | $11.5B | $-1.1B |
| Q4 25 | $16.4B | $26.4B | ||
| Q3 25 | $17.1B | $26.8B | ||
| Q2 25 | $17.3B | $27.3B | ||
| Q1 25 | $17.0B | $26.4B | ||
| Q4 24 | $16.6B | $26.5B | ||
| Q3 24 | $17.5B | $26.5B | ||
| Q2 24 | $18.4B | $26.5B | ||
| Q1 24 | $19.0B | $26.9B |
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.31× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $388.5M | $495.0M |
| Free Cash FlowOCF − Capex | $233.1M | $403.0M |
| FCF MarginFCF / Revenue | 16.3% | 14.4% |
| Capex IntensityCapex / Revenue | 10.9% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $692.5M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.5M | $495.0M | ||
| Q3 25 | $355.6M | $405.0M | ||
| Q2 25 | $-7.2M | $289.0M | ||
| Q1 25 | $545.4M | $211.0M | ||
| Q4 24 | $674.0K | $601.0M | ||
| Q3 24 | $240.5M | $405.0M | ||
| Q2 24 | $362.9M | $380.0M | ||
| Q1 24 | $98.0M | $211.0M |
| Q4 25 | $233.1M | $403.0M | ||
| Q3 25 | $223.4M | $314.0M | ||
| Q2 25 | $-126.8M | $190.0M | ||
| Q1 25 | $362.8M | $96.0M | ||
| Q4 24 | $-355.1M | $495.0M | ||
| Q3 24 | $-62.6M | $334.0M | ||
| Q2 24 | $-84.7M | $302.0M | ||
| Q1 24 | $-481.4M | $129.0M |
| Q4 25 | 16.3% | 14.4% | ||
| Q3 25 | 17.1% | 11.7% | ||
| Q2 25 | -9.5% | 7.5% | ||
| Q1 25 | 33.7% | 4.2% | ||
| Q4 24 | -28.8% | 19.3% | ||
| Q3 24 | -4.6% | 13.3% | ||
| Q2 24 | -5.9% | 12.6% | ||
| Q1 24 | -35.4% | 6.0% |
| Q4 25 | 10.9% | 3.3% | ||
| Q3 25 | 10.1% | 3.4% | ||
| Q2 25 | 9.0% | 3.9% | ||
| Q1 25 | 17.0% | 5.1% | ||
| Q4 24 | 28.9% | 4.1% | ||
| Q3 24 | 22.4% | 2.8% | ||
| Q2 24 | 31.3% | 3.2% | ||
| Q1 24 | 42.6% | 3.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | -0.31× | 1.95× | ||
| Q1 25 | 13.19× | — | ||
| Q4 24 | 0.01× | 6.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 38.00× | ||
| Q1 24 | 40.01× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALB
| Energy Storage | $759.1M | 53% |
| Specialties | $348.9M | 24% |
| Ketjen | $320.1M | 22% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
